CNBCLean R·
JPMorgan says this biotech stock can more than double following steep declines
The investment bank initiated coverage with an overweight rating.
Read at CNBC →
The investment bank initiated coverage with an overweight rating.
<iframe src="https://statesidedaily.com/embed/cluster/2065c1d548b048c48382d04b5212917ca0472d20" width="100%" height="320" style="border:0;max-width:680px" loading="lazy" title="JPMorgan says this biotech stock can more than double following steep declines"></iframe>